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Abstract
Myeloid dendritic cells, including BDCA3hi DCs and BDCA1+ DCs (hereafter
dubbed DC1 and DC2 for clarity), play a pivotal role in the induction and
regulation of immune responses. Interestingly, a fraction of DC2 also express
low to intermediate levels of BDCA3. It is unknown whether BDCA3+ DC2
also share other traits with DC1 that are absent in BDCA3 DC2 and/or
whether BDCA3 expression renders DC2 functionally distinct from their
BDCA3-lacking counterparts. Here, we used expression analysis on a
predefined set of immunology-related genes to determine divergence between
BDCA3-positive and BDCA3-negative DC2 and their relation to bona fide
BDCA3hi DC1. Results showed that mRNA fingerprints of BDCA3+ DC2 and
BDCA3 DC2 are very similar, and clearly distinct from that of DC1.
Differences in mRNA expression, however, were observed between BDCA3+
DC2 and BDCA3 DC2 that pointed toward a more activated status of
BDCA3+ DC2. In line with this, higher steady state maturation marker
expression and TLR-induced maturation marker expression and inflammatory
cytokine production by BDCA3+ DC2 were observed. This dataset provides
insight into the relationship between myeloid DC populations and contributes
to further understanding of DC immunobiology.
INTRODUCTION
Dendritic cells (DCs) are professional antigen-presenting
cells located in peripheral blood, lymphoid and non-
lymphoid tissues, where they sample the environment
for invading pathogens. Recognition of foreign antigens
induces activation of DCs, which is associated with
upregulation of several surface receptors and production
of cytokines that enable DCs to migrate to secondary
lymph nodes and to activate T cells and other immune
cells.1 The human DC family comprises several subsets,
including BDCA2+BDCA4+ plasmacytoid DCs, BDCA1+
myeloid DCs, also referred to as DC2, and BDCA3hi
CLEC9A+XCR1+ (DC1) myeloid DCs.2 The markers
BDCA1, BDCA2, BDCA3 and BDCA4 are generally
used to classify human DC. However, BDCA3 is not
exclusively expressed by DC1, but also at intermediate
levels by other DCs, such as DC2 in blood,3,4 and even
more so by DC2 in lymphoid tissues5 and nonlymphoid
tissues.6
BDCA3, also known as CD141 or thrombomodulin, is
a cell surface-expressed transmembrane glycoprotein. On
vascular endothelial cells, BDCA3 is known for its
anticoagulant activity, and has been described to have an
anti-inflammatory function as it blocks proinflammatory
proteins and activates anti-inflammatory proteins and
inhibitors of the complement system.7,8 However, the
exact function of BDCA3 expression on immune cells is
not completely understood. Although DC2 have been
shown to represent a subset that is distinct from DC1,6,9
it is possible that the expression of BDCA3 endows
them with distinct functional properties or indicates a
closer relation to DC1. Here, we compared the
expression signature of predefined immune-related genes
of BDCA3+ DC2, BDCA3 DC2 and DC1, and
investigated the presence of differences between BDCA3+
and BDCA3 DCs within the DC2 population. Results
showed that although BDCA3+ DC2 and BDCA3 DC2
are highly comparable and distinct from bona fide
DC1, BDCA3-positive DC2 have a more activated status
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than DC2 that do not express BDCA3, and produce
higher levels of cytokines upon TLR activation.
RESULTS AND DISCUSSION
Immunology-related gene expression patterns of
BDCA3+ DC2 are similar to those of BDCA3 DC2
To assess how BDCA3+ DC2 relate to their BDCA3-
negative counterpart, DC populations shown in Figure 1a
were sorted and expression of a set of 579 preselected
immunology-related genes was analyzed by multiplex gene
expression analysis (for complete list of obtained gene
expression values, see Supplementary table 1). BDCA3
expression on DC2 was highly variable between donors
and ranged from 41% to 85% (Figure 1a, Supplementary
figure 1). Of note, purity of magnetic bead and flow
isolated DC populations was above 98% and populations
were free of non-DC contaminants (Supplementary figure
2). Sample clustering and principal component analysis
revealed a high level of overlap between the immunology-
related gene expression profile of DC1, BDCA3 DC2 and
BDCA3+ DC2 (Figure 1b and c). BDCA3+ DC2 and
BDCA3 DC2, however, appeared far more comparable to
each other than to DC1 (Figure 1b and c). Although
BDCA3 DC2 and BDCA3+ DC2 were found to be very
similar, some minor differences in immunology-related
gene expression levels were observed (Figure 1b).
Comparison of DC1 and BDCA3+ DC2
In total, 10 genes showed a trend toward differential
expression between BDCA3+ DC2 and BDCA3 DC2 by
t-testing, but the difference was significant for none after
applying multiple testing correction (Figure 1d). To test the
hypothesis that BDCA3+ DC2 may resemble DC1 more than
BDCA3 DC2 does, we investigated whether these 10 genes
were also higher expressed in bona fide DC1. Interestingly,
nine of those genes were also differentially expressed
between BDCA3 DC2 and DC1 (up in BDCA3hi DCs:
SLAMF7, CD83, SRC, CXCR3, and down: CD99, STAT5A,
PRKCD, CD4, IRF4), indicating that BDCA3 expression on
DC2 is accompanied by a trend for higher expression of
other genes also highly expressed by DC1 (Figure 2a). A
complete list of genes differentially expressed between DC1
and BDCA3 DC2 is provided in Supplementary table 2.
Gene Set Enrichment Analysis can be used to test a
broad spectrum of genes on whether the differences in
expression pattern observed between two cell types (e.g.
DC1 and DC2) resembles the pattern observed between
two other cell types (e.g. BDCA3+ and BDCA3 DC2). For
this analysis two gene sets containing the top 50 genes
higher and lower expressed in DC1 compared to BDCA3
DC2 were generated by simple fold-change calculation
(genes included in each set are indicated in Supplementary
table 3). As expected, the DC1-overexpressed gene set
contained the DC1 hallmark genes TLR3, BATF3 and
XCR1,10 and antigen (cross)-presentation-related genes
(HLA, PSMB, TAP; DC1 > DC2, Supplementary table 3).
The DC2-overexpressed gene set, in contrast, included the
pathogen recognition receptor TLR4 for bacterial
recognition and ITGAM, the alpha subunit of the MAC-1
integrin heterodimer that facilitates phagocytosis
(DC2 > DC1, Supplementary table 3).11–13
When applying Gene Set Enrichment Analysis to
visualize the distribution of these two sets of 50 genes on
the immune-related genes ranked on expression
difference between BDCA3+ DC2 compared to BDCA3
DC2, we observed that the majority, but not all, of the
DC1 over-expressed gene set was also higher expressed in
BDCA3+ DC2 relative to DC2 lacking BDCA3
(Figure 2b). Enrichment of the gene set in BDCA3+ DC2,
however, was not overwhelming (normalized enrichment
score 1,6; false discovery rate q-value 0.285, Figure 2b).
Genes lower expressed in DC1 were also, more often than
not, lower in BDCA3-positive DC2, but the negative
enrichment (i.e. depletion) of this gene set was even less
apparent (normalized enrichment score 1.5; false
discovery rate q-value 0.925, Figure 2c).
Finally, the expression of several established hallmark
genes of either DC1 or DC2 was assessed for each gene
individually. For these key genes, BDCA3-positive DC2
behaved comparably to their BDCA3-lacking counterparts
(Figure 2d and e). Importantly, BDCA3+ DC2 and
BDCA3 DC2 expressed equal levels of the transcription
factors IRF8 and BATF3, which together have been shown
to be expressed in and to regulate differentiation into
DC1.9,14–16 Furthermore, BDCA3+ DC2 expressed more
IRF4, which has been associated with differentiation into
DC2.17,18 These results suggest that even though BDCA3+
DC2 may resemble DC1 slightly more than do their
BDCA3 counterparts, this seems not to be an effect of
these fate-determining transcription factors. In line with
this, BDCA3+ DC2 did not express any transcripts for
XCR1, which was highly abundant in DC1 and is
considered the hallmark gene for DC1 (Supplementary
table 1 and Figure 2).3 Additionally, DC1 marker
CLEC9A, which was not one of the immune-related genes
measured by RNA multiplex, was absent on BDCA3+ DC2
by flow cytometry (Supplementary figure 2).
BDCA3+ DC2 have a higher cytokine-producing
capacity than BDCA3 DC2
To get more insight into the DC1 genes that were also
higher in BDCA3+ DC2 and to derive functional
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Figure 1. Gating strategy and expression profiles of immunology-related genes. (a) Peripheral blood mononuclear cells were isolated from
healthy controls and enriched for DCs using a Dynabeads Human DC Enrichment kit. Duplicates were excluded based on size, and DC
populations were subsequently identified as BDCA3hi cells (DC1), BDCA3+BDCA1+ cells (BDCA3+ DC2) and BDCA3BDCA1+ cells (BDCA3 DC2).
Representative results of three different donors in three different experiments are shown. (b-d) mRNA isolated from DC populations of 2 or 3
different donors sorted in three different experiments was pooled per sample and gene expression levels were measured using the NanoString
nCounter system. (b) Log2 expression levels of genes that were expressed in at least one of the three DC subtypes (expression level > 50) are
shown in a heatmap. Hierarchical clustering was performed using Pearson correlation. The black arrow indicates differential gene expression
between BDCA3+ DC2 and BDCA3 DC2. (c) Principal component analysis was performed using the MeV software, based on genes expressed in
at least one of the three DC subtypes (expression level > 50). PC1 accounts for 52% and PC3 for 8% of the total variance. Each point represents
a sample, classified by DC type. (d) Genes differentially expressed in BDCA3+ DC2 as compared to BDCA3 DC2, P < 0.05 by an unpaired
Student’s t-test not corrected for multiple testing (MR). Bonferroni corrected a-value = 0.00016, rendering none of these genes significant after
MT correction.
3
E van der Aa et al. Comparison of BDCA3+ DC2 and BDCA3 DC2
implications, we inspected more closely the genes higher
expressed in these two cell populations compared to
BDCA3 DC2. Enhanced expression of (I) SLAMF7,19 a
CD2 family receptor expressed by mature DCs; (II) CD83,
a DC maturation marker; (III) SRC,20 a protein tyrosine
kinase which is activated following engagement of many
different classes of cellular receptors; (IV) IRF4,21 a
transcription factor associated with induction of a Th2
response by DCs and (V) the chemokine receptor CXCR3;
as well as reduced expression of (VI) TOLLIP,22 a
ubiquitin-binding protein that negatively regulates TLR-
mediated signaling, suggested a more activated status and
possibly differential cytokine production by BDCA3+ DC2
compared to BDCA3 DC2. To further investigate this,
activation marker expression on freshly isolated cells, and
maturation and cytokine-producing capacity after in vitro
TLR stimulation, were assessed. Directly after isolation,
CD40, CD83 and CD86 expression, but not CD80
expression, was significantly higher on BDCA3+ DC2
compared to BDCA3 DC2, confirming a more activated
status of these cells (Figure 2f and g). Furthermore, upon
culture with or without TLR ligands polyI:C, R848 and
LPS, CD83 and CD86 expression was more enhanced on
BDCA3+ DC2 compared to BDCA3 DC2 (Figure 3a).
Although CD80 was not differentially expressed on freshly
isolated DC, CD80 was augmented on BDCA3+ DC2
compared to BDCA3 DC2 upon culture (Figure 3a). The
opposite we observed for CD40 that was differentially
Figure 2. Analysis of DC population gene signatures and activation status. (a–e) mRNA isolated from DC populations of 2 or 3 different donors
sorted in three different experiments was pooled per sample. Gene expression levels were measured using the NanoString nCounter system. (a)
The Venn diagram represents the number of genes significantly differentially expressed between the indicated DC populations (P < 0.05,
unpaired t-test). (b, c) Enrichment plots of Gene Set Enrichment Analysis performed using the DC1-overexpressed gene set, DC2-overexpressed
gene set (Supplementary table 3) and a ranked list containing genes ranked by fold-change in expression values between BDCA3+ DC2 compared
to BDCA3 DC2. For statistical analysis, the gene sets were complemented by the curated C2 gene sets published on software.broadinstitute.org
to properly determine the normalized enrichment score, nominal P-value (NOM P-val) and false discovery rate. (d, e) Normalized expression of
hallmark genes of DC1 (d) or DC2 (e) by the different DC populations. (f, g) Mean fluorescence intensity (f) and percentage of cells expressing
the indicated markers (g) were measured on freshly isolated DC by flow cytometry. Data of six independent experiments, performed with 11
different donors, are shown. *P < 0.05, **P < 0.01, paired Student’s t-test.
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Figure 3. Maturation marker expression and cytokine production upon stimulation. BDCA3+ DC2 and BDCA3 DC2 were FACSorted from
Peripheral blood mononuclear cells enriched for DCs and stimulated for 24 h with or without polyI:C, R848 or LPS. (a) Expression of CD40,
CD80, CD83 and CD86 was measured by flow cytometry. Percentage of cells expressing the indicated markers is shown. Data of two
independent experiments, performed with three different donors, are shown. *P < 0.05, ***P < 0.001, paired Student’s t-test. (b)
Mean  s.e.m. cytokine levels as determined by ELISA (n = 5). Data are pooled from two independent experiments, performed with five different
donors. *P < 0.05, paired Student’s t-test.
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expressed on fresh DCs, but not upon culture in the
presence or absence of TLR ligation (Figure 2f and g,
Figure 3a). Furthermore, upon stimulation with polyI:C
or R848, IL-1b, IL-6, IL-8 and TNF-a production was
consistently higher for BDCA3+ DC2 compared to
BDCA3 DC2 (Figure 3b). TLR3, TLR4 or TLR8
expression levels were not significantly different between
BDCA3+ DC2 and BDCA3 DC2, indicating that a
difference in TLR levels was not the underlying cause for
the observed differences (Figure 2d and e, Supplementary
table 1). Together, our data indicate that BDCA3+ DC2
have an enhanced activation status, reflected by a higher
costimulatory molecule expression and cytokine-
producing capacity as compared to their BDCA3
counterparts.
The association between BDCA3 expression in vivo and
enhanced DC activation and cytokine production is in line
with an increase in BDCA3 expression on pDCs and DC2
upon maturation of these cells in vitro.23 In addition,
BDCA3 expression is upregulated on monocyte-like cells
upon TNF-a and IL-1b stimulation,24 and also associated
with increased IFN-k-producing capacity by CD34+-
derived DCs.25 BDCA3 is also higher expressed on DC2 in
peripheral tissues compared to DC2 in peripheral blood.6
Previously, functional comparison of BDCA3+ and
BDCA3 monocyte-derived DC (moDC) showed that
BDCA3+ moDC induced a more strongly Th2-polarized
response compared to BDCA3 moDC.26 As BDCA3 has
been described to exhibit direct and indirect anti-
inflammatory functions,7,8,27 it is tempting to speculate that
although BDCA3 is expressed on more activated DCs,
BDCA3 may play a role in dampening and/or balancing
proinflammatory responses.
The gene expression dataset presented here is valuable
for the study of DC immunobiology, as it provides useful
information regarding phenotypic, functional and
developmental characteristics of the different DC
subpopulations and the relationship between the marker
BDCA3 and cell function. Nevertheless, further research
is required to determine the exact function of BDCA3
expression on DC2 or other DC subsets.
METHODS
Cell isolation
Peripheral blood mononuclear cells were isolated from
heparinized peripheral blood samples or buffy coats from
healthy donors using Ficoll density gradient centrifugation.
The study was approved by the medical ethical committee of
the Erasmus MC University Medical Center and donors gave
written informed consent before blood donation. Cells were
enriched for DCs using Dynabeads (Life Technologies AS,
Oslo, Norway) and DC subsets were isolated based on
BDCA1, BDCA3 and BDCA4 expression by FACSorting.
Flow cytometric analysis
For phenotypic analysis, cells were labeled with fluorochrome-
conjugated antibodies recognizing BDCA3/CD141 (Miltenyi
Biotec, Leiden, The Netherlands); BDCA1/CD1c (Miltenyi
Biotec and Biolegend UK Ltd, London, UK), BDCA4/CD304
(Biolegend UK Ltd), CD3, CD11c, CD14, CD19, CD56, HLA-
DR, CD40, CD80, CD83 (all eBiosciences, Fisher Scientific,
Landsmeer, The Netherlands), CD86 (BD Horizon), CLEC9A
(ITK Diagnostics, Uithoorn, The Netherlands) and CD11b
(Becton Dickinson BV, Breda, The Netherlands).
Gene expression analysis using Nanostring
nCounter system
RNA was extracted using an RNAeasy Micro kit or a Nucleospin
RNA II kit for samples containing <5 9 105 or >5 9 105 cells,
respectively. RNA concentration and integrity was assessed
using a Bioanalyzer system (Agilent Technologies, Santa Clara,
CA, USA). Human immunology-related genes were profiled
using the nCounter GX Human Immunology v2 kit Gene
Expression CodeSet (Nanostring Technologies, Seattle, WA,
USA). Gene expression levels were normalized according to 15
housekeeping genes. Gene clustering analysis was performed
using GENE-E software (http://www.broadinstitute.org/cancer/sof
tware/GENE-E/). Principal component analysis was performed
using MeV (4.9.0) software http://www.tm4.org/mev.html. Gene
set enrichment analysis was performed using Gene Set
Enrichment Analysis software.28
DC activation and cytokine secretion
FACSorted DCs were stimulated with or without polyI:C
(20 lg mL1; Invivogen, Toulouse, France), LPS
(200 ng mL1; Invivogen) or R848 (1 lg mL1; Enzo Life
Sciences, Brussels, Belgium) for 24 h at 37°C in the presence
of 10 ng mL GM-CSF (Enzo Life Sciences). The levels of
secreted human IL-1b, IL-6, IL-8 and TNF-a were measured
in the supernatant using ELISA (eBioscience).
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